Novartis AG
Treatment of cancer using GFR .alpha.-4 chimeric antigen receptor
Last updated:
Abstract:
The present invention relates to compositions and methods for treating diseases, disorders or conditions associated with the expression of the Glycosyl-phosphatidylinositol (GPI)-linked GDNF family .alpha.-receptor 4 (GFR.alpha.4).
Status:
Grant
Type:
Utility
Filling date:
14 Aug 2015
Issue date:
1 Dec 2020